Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.64 |
| ▸ | CNR1 | P21554 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.44 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3987749 | 0.99 | CNR2 (0.63) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13692153 | 0.99 | CNR2 (0.65) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL3988653 | 0.98 | CNR2 (0.64) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13692088 | 0.92 | CNR2 (0.61) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13691903 | 0.91 | CNR1 (0.77) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL3990528 | 0.91 | CNR2 (0.61) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13692157 | 0.91 | CNR2 (0.65) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL3992692 | 0.90 | CNR1 (0.76) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13692125 | 0.90 | CNR1 (0.61) | CNR2CNR1CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL3988849 | 0.90 | CNR2 (0.64) | CNR2CNR1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | claimed |
| EP-1753764-B1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2008-10-29 | — | — | EP | claimed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | claimed |
| CN-101001859-A | Pyrrolopyridine derivatives | GLAXO GROUP LTD (GB) | 2007-07-18 | — | — | CN | claimed |
| EP-1753764-A1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-02-21 | — | — | EP | claimed |
| WO-2005121140-A1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-22 | — | — | WO | claimed |
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| US-7589206-B2 | Pyrrolopyridine derivatives | GLAXO GROUP LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1753764-B1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| US-20070219229-A1 | Pyrrolopyridine Derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | US | disclosed |
| CN-101001859-A | Pyrrolopyridine derivatives | GLAXO GROUP LTD (GB) | 2007-07-18 | — | — | CN | disclosed |
| EP-1753764-A1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005121140-A1 | PYRROLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219229-A1 | Pyrrolopyridine Derivatives | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885CYP3A4 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.